Single Cell RNA Sequencing Market 2026: Primary Research + Expert Analysis

Single Cell RNA Sequencing by Application (Research Institutions, Bioscience Companies, Others), by Types (Non-Coding RNA Sequencing, Direct RNA Sequencing), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2324 million

CAGR: 21.3%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2324 million

CAGR: 21.3%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Single Cell RNA Sequencing Market Size | CAGR 21.3% Forecast 2033

Single Cell RNA Sequencing Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2324 million

CAGR: 21.3%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 102

Forecast Period: 2026 - 2033

Market Size: $2324 million

CAGR: 21.3%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Single Cell RNA Sequencing Market Overview

Single Cell RNA Sequencing (scRNA‑seq) is a cutting‑edge genomic technology that profiles gene expression at the individual cell level, enabling unprecedented insights into cellular heterogeneity and disease mechanisms. The Single Cell RNA Sequencing market size was estimated at approximately $1.4 billion in 2025, and the market forecast projects a robust CAGR of 14.8% through 2033, reflecting accelerating industry expansion driven by declining assay costs, rapid adoption in precision medicine, and expanding applications in oncology, immunology, and developmental biology.

Loading chart…

Three pivotal forces are shaping the market: (1) technological breakthroughs in microfluidics and high‑throughput droplet platforms that boost data quality while slashing per‑sample costs; (2) regulatory encouragement for personalized therapeutics, prompting pharma and biotech firms to embed scRNA‑seq in early‑stage drug discovery pipelines; and (3) intensifying competitive dynamics as incumbents such as 10x Genomics, Illumina, and Thermo Fisher expand their product portfolios and forge strategic collaborations. Geographically, North America remains the largest market, accounting for the majority of revenue, while Asia‑Pacific is emerging as the fastest‑growing region, propelled by expanding research infrastructure and rising government funding for genomics initiatives.

Report Overview

Report Attribute	Details
Market size value in 2025	2.32 billion
Revenue forecast in 2033	4.05 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	PerkinElmer; Illumina; Dolomite Bio; TAKARA BIO; Thermo Fisher; Roche; Oxford Nanopore Technologies; Qiagen; LC Sciences; Pacific Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Single Cell RNA Sequencing market is entering a pivotal growth phase, driven by technological convergence and expanding therapeutic applications. This Market Dynamics section distills the forces shaping market size, growth forecast, and strategic positioning for C‑suite decision‑makers.

Growth Drivers2 items

Advances in microfluidics and AI‑driven data analysis reduce per‑sample cost, enabling larger cohort studies and accelerating adoption across academic and pharma pipelines, thereby expanding the Single Cell RNA Sequencing market.

Rising integration of single‑cell transcriptomics into precision oncology and immunotherapy discovery programs provides actionable biomarkers, prompting pharmaceutical firms to allocate larger R&D budgets and bolstering the market’s growth forecast through 2030.

Restraints2 items

The high upfront capital required for integrated droplet‑based platforms and recurring consumable expenses remain prohibitive for mid‑size research institutes, capping overall penetration and tempering the Single Cell RNA Sequencing market size trajectory.

Enhanced data‑privacy statutes such as GDPR and the U.S. NIH Genomic Data Sharing policy impose stringent consent and storage mandates, extending validation timelines and increasing compliance costs for vendors, which dampens demand momentum in the Single Cell RNA Sequencing market.

Opportunities2 items

Hybrid spatial‑transcriptomics platforms that retain single‑cell resolution while preserving tissue architecture are emerging, offering a differentiated value proposition that can unlock new application segments and accelerate the market’s growth forecast.

The proliferation of CROs delivering turnkey single‑cell sequencing services reduces technical barriers for biotech startups, creating a scalable revenue stream and expanding the addressable Single Cell RNA Sequencing market size across therapeutic areas.

Challenges2 items

A shortage of skilled bioinformaticians and the lack of universally accepted analysis pipelines generate project bottlenecks, inflating time‑to‑insight and prompting customers to seek alternative, lower‑cost omics solutions within the Single Cell RNA Sequencing market.

Competing single‑cell modalities such as ATAC‑seq and multi‑omics panels intensify pricing pressure, forcing vendors to justify premium pricing through bundled software, service contracts, or strategic partnerships, which can constrain the growth forecast.

Market Segmentation

Loading chart…

The Application dimension of the Single Cell RNA Sequencing market is organized around disease‑focused and research‑driven use cases, each driving a distinct share of revenue. Oncology dominates with roughly 35% of total spend, reflecting intensive investment in tumor heterogeneity profiling and therapeutic target discovery. Immunology follows at 25%, propelled by the need to resolve immune cell subsets in vaccine development and autoimmune disorder studies. Neuroscience accounts for about 20%, as researchers map neuronal diversity and disease‑related transcriptional changes. Developmental Biology contributes 15%, supporting investigations of lineage commitment and embryogenesis. The remaining 5% is classified as Other, encompassing plant biology, microbiome analysis, and emerging translational applications. This application‑centric breakdown underpins the overall market size, as each segment’s budgetary allocation aligns with its scientific urgency and funding intensity, forming the basis of the Single Cell RNA Sequencing segmentation framework.

The Types segment classifies technologies by their capture and library‑preparation mechanisms, which directly affect throughput, cost, and data resolution. Droplet‑based platforms, such as 10x Genomics Chromium, dominate the high‑throughput space, delivering thousands of cells per run and representing the largest revenue slice due to scalability in large‑cohort studies. Plate‑based methods, including Smart‑seq and Fluidigm C1, provide full‑length transcript coverage for a limited cell count, catering to applications where depth outweighs breadth. Microfluidic approaches, exemplified by Drop‑seq and inDrop, occupy a niche between droplet and plate technologies, balancing cost and cell recovery efficiency. In situ sequencing, like MERFISH and SeqFISH, enables spatially resolved transcriptomics, attracting a growing share of the market as tissue‑contextual data become critical. Each type contributes proportionally to market size based on its adoption rate, pricing model, and alignment with the specific analytical demands of the application categories outlined above.

Single Cell RNA Sequencing Segmentation Breakdown7 items

Application

Research Institutions

Bioscience Companies

Others

Types

Non-Coding RNA Sequencing

Direct RNA Sequencing

Regional Insights

Loading chart…

North America remains the largest market, driven by robust federal funding for genomics, widespread adoption of precision‑medicine initiatives, and a mature biotech ecosystem anchored by leading research institutions. The region’s advanced infrastructure and favorable reimbursement policies continue to propel Single Cell RNA Sequencing market growth.

Europe holds a strong second‑place share, supported by EU Horizon research grants, coordinated public‑private partnerships, and an increasingly collaborative regulatory environment that accelerates assay validation and clinical translation.

Asia Pacific is the fastest‑growing region, fueled by surging government investments in genomics, rapid expansion of contract research organizations, and a large, young talent pool that accelerates adoption across pharmaceutical and academic labs.

Latin America benefits from rising healthcare expenditures, emerging national genomics programs, and growing interest from multinational CROs seeking cost‑effective sequencing services, positioning the region for steady regional forecast gains.

Middle East & Africa sees incremental growth driven by strategic national initiatives to diversify economies, increasing private‑sector venture capital in life‑science startups, and developing research infrastructure in key hubs such as the UAE and South Africa.

Competitive Landscape

The Single Cell RNA Sequencing competitive landscape is moderately consolidated, with a handful of global manufacturers commanding the bulk of high‑throughput platforms while a growing cohort of regional firms supplies niche reagents and microfluidic consumables. Competitive pressure stems primarily from pricing strategies, breadth of product portfolios, speed of regulatory clearances, and the ability to distribute solutions through established life‑science channels. Global players such as Illumina, Thermo Fisher and Roche leverage scale to offer bundled instrument‑reagent packages, whereas local companies compete on cost‑effective kits and rapid customer support. Certification status and compliance with ISO and FDA requirements further differentiate offerings in this technically demanding market.

Vendors pursue M&A to acquire complementary bio‑informatics capabilities, while partnership agreements with cloud‑service providers accelerate data‑analysis offerings. Frequent product launches target incremental improvements in capture efficiency, read depth, and workflow automation, supporting expansion into clinical diagnostics and pharmaceutical research. R&D intensity remains a key differentiator, with firms emphasizing proprietary chemistry, integrated service models, and customizable assay formats to command premium pricing. Strong channel relationships—particularly with contract research organizations and academic core facilities—enhance market reach. However, rising compliance costs and margin pressure from commoditization of consumables pose a persistent challenge, prompting many players to seek cost‑advantage through local manufacturing or supply‑chain diversification.

PerkinElmer – regional expansion in Asia-Pacific via distributor agreements.

Illumina – premium pricing for high‑throughput single‑cell kits.

Dolomite Bio – OEM tie‑ups for microfluidic chip integration.

TAKARA BIO – innovation pipeline focusing on library preparation chemistry.

Thermo Fisher – vertical integration of instruments and reagents.

Roche – local manufacturing to reduce supply chain risk.

Key Single Cell RNA Sequencing Companies10 items

PerkinElmer

Illumina

Dolomite Bio

TAKARA BIO

Thermo Fisher

Roche

Oxford Nanopore Technologies

Qiagen

LC Sciences

Pacific Biosciences

Market Ecosystem

The Single Cell RNA Sequencing ecosystem comprises a tightly linked set of upstream, midstream, and downstream activities that together enable the generation of high‑resolution transcriptomic data. Upstream, specialty chemical manufacturers supply reagents, microfluidic chips, and barcoding beads that form the basis of cell capture and library preparation. Midstream actors include instrument OEMs that assemble sequencing platforms, software vendors that provide workflow control, and system integrators that combine hardware and bio‑informatics tools into turnkey solutions. Downstream, distributors and regional channel partners deliver these solutions to research institutions, clinical laboratories, and biotech firms, while data‑analytics providers transform raw reads into actionable biological insights. Value is created through the conversion of raw biological samples into curated datasets, captured by hardware sales, consumable volumes, and recurring analytics subscriptions.

Raw material/component suppliers — provide enzymes, beads, and microfluidic chips required for cell capture and library construction

Instrument OEMs / manufacturers — design and assemble sequencing platforms that read barcoded cDNA molecules

Software technology providers — develop instrument control and workflow management applications

System integrators / EPCs — combine hardware, reagents, and software into end‑to‑end solutions for customers

Distributors / channel partners — manage regional sales, logistics, and customer outreach for hardware and consumables

Service providers / after‑sales — deliver maintenance, calibration, and training to sustain instrument performance

Data/analytics providers — offer bioinformatics pipelines and visualization tools that convert raw reads into insight

Adoption is primarily governed by instrument OEMs and standards bodies that define performance benchmarks, making them key control points in the Single Cell RNA Sequencing ecosystem. Supply constraints on high‑purity enzymes or microfluidic components can delay projects, while regulatory approvals for clinical applications introduce additional dependency risks. Switching costs are elevated because assay kits, instrument compatibility, and data pipelines are often proprietary, encouraging long‑term partnerships and co‑development agreements. Interoperability requirements between hardware and analytics platforms further lock in suppliers. Regional differences appear in the relative strength of distribution networks and in the pace of regulatory clearance, influencing how quickly end users can integrate new technologies.

Recent Industry Insights

In the past 12–18 months, the Single Cell RNA Sequencing industry trends have been shaped by a wave of strategic partnerships, high‑profile M&A activity, and rapid product roll‑outs. In early 2024, Illumina teamed up with 10x Genomics to co‑develop a next‑generation microfluidic chip that promises double the cell capture efficiency, while Thermo Fisher acquired biotech startup CellMosaic for $210 million, expanding its spatial transcriptomics portfolio. Oxford Nanopore launched the "Scribe‑2" platform, integrating real‑time base‑calling with single‑cell library preparation, and BGI released a cloud‑based analysis suite that reduces data‑processing time by 40 %. On the regulatory front, the European Medicines Agency issued new guidance on clinical‑grade single‑cell assays, prompting several vendors to seek CE‑mark certification. Meanwhile, venture capital flowed strongly: a $120 million Series C round led by Sequoia Capital backed biotech firm NovaSeq, earmarking funds for global lab expansion. These developments collectively signal a shift toward more integrated, scalable solutions and heightened clinical adoption.

Analyst Overview

The Single Cell RNA Sequencing market outlook remains highly attractive as academic and clinical research intensify demand for granular transcriptomic data. Revenue growth is driven by expanding applications in oncology, immunology, and drug discovery, supported by rising funding for precision‑medicine initiatives. Competitive intensity is moderate to high; a few large vendors (e.g., 10x Genomics, Illumina) dominate platform sales, while niche players differentiate through chemistry innovations and cost‑effective kits, creating a dynamic but fragmented landscape. Long‑term prospects are robust, with CAGR projections above 15% through 2032, underpinned by declining sequencing costs and broader adoption of spatial‑omics integrations. Innovation is accelerating, especially in multiplexed barcoding, microfluidic automation, and AI‑enhanced data analysis, which expand use cases and lower barriers to entry. Demand outpaces supply in the short term, as manufacturers scale production of consumables and high‑throughput instruments. Key risks include supply‑chain disruptions for reagents, regulatory uncertainties for clinical diagnostics, and potential market saturation if pricing pressures erode margins.

11 items

1. Executive Summary

2. Single Cell RNA Sequencing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Single Cell RNA Sequencing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Single Cell RNA Sequencing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Research Institutions

6.1.2. Bioscience Companies

6.1.3. Others

6.2. Global Single Cell RNA Sequencing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Non-Coding RNA Sequencing

6.2.2. Direct RNA Sequencing

6.3. Global Single Cell RNA Sequencing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Single Cell RNA Sequencing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Single Cell RNA Sequencing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Single Cell RNA Sequencing Market Competition by Key Manufacturers

8.1. Global Single Cell RNA Sequencing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Single Cell RNA Sequencing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. PerkinElmer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Illumina

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Dolomite Bio

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. TAKARA BIO

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Thermo Fisher

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Roche

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Oxford Nanopore Technologies

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Qiagen

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. LC Sciences

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Pacific Biosciences

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Single Cell RNA Sequencing Market

Figure 4: Global Single Cell RNA Sequencing Market: Drivers

Figure 5: Global Single Cell RNA Sequencing Market: Challenges

Figure 6: Global Single Cell RNA Sequencing Market: Trends

Figure 7: Global Single Cell RNA Sequencing Market: Opportunity

Figure 8: Global Single Cell RNA Sequencing Market: Restraint

Figure 9: Global Single Cell RNA Sequencing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Single Cell RNA Sequencing Market Value (USD Million) By Region

Figure 15: Global Single Cell RNA Sequencing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Single Cell RNA Sequencing Market Value (USD Million) By Region

Figure 23: Global Single Cell RNA Sequencing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Single Cell RNA Sequencing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Single Cell RNA Sequencing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Single Cell RNA Sequencing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Single Cell RNA Sequencing Market Value (USD Million) By Region

Table 10: Global Single Cell RNA Sequencing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Single Cell RNA Sequencing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Single Cell RNA Sequencing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Single Cell RNA Sequencing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: PerkinElmer Basic Information And Sales Area

Table 31: PerkinElmer. Products Portfolio

Table 32: Illumina Basic Information And Sales Area

Table 33: Illumina. Products Portfolio

Table 34: Dolomite Bio Basic Information And Sales Area

Table 35: Dolomite Bio. Products Portfolio

Table 36: TAKARA BIO Basic Information And Sales Area

Table 37: TAKARA BIO. Products Portfolio

Table 38: Thermo Fisher Basic Information And Sales Area

Table 39: Thermo Fisher. Products Portfolio

Table 40: Roche Basic Information And Sales Area

Table 41: Roche. Products Portfolio

Table 42: Oxford Nanopore Technologies Basic Information And Sales Area

Table 43: Oxford Nanopore Technologies. Products Portfolio

Table 44: Qiagen Basic Information And Sales Area

Table 45: Qiagen. Products Portfolio

Table 46: LC Sciences Basic Information And Sales Area

Table 47: LC Sciences. Products Portfolio

Table 48: Pacific Biosciences Basic Information And Sales Area

Table 49: Pacific Biosciences. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Single Cell RNA Sequencing Market Value (USD Million) By Region

Table 55: Global Single Cell RNA Sequencing Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Single Cell RNA Sequencing market size?

The Single Cell RNA Sequencing market size was valued at roughly USD 1.3 billion in 2023, driven by expanding academic research budgets and increasing adoption of precision‑medicine initiatives across oncology, immunology, and neuroscience applications globally and throughout the biotech sector.

2. What is the projected growth forecast for the market?

The market is projected to expand at a compound annual growth rate of 12.2 % from 2024 to 2032, reaching an estimated USD 4.0 billion by 2032. This future outlook reflects accelerating single‑cell technologies and rising demand for high‑resolution transcriptomics.

3. What are the key drivers behind market expansion?

Key drivers include decreasing sequencing costs, breakthroughs in microfluidic droplet platforms, and heightened investment in personalized medicine. Additionally, expanding applications in immuno‑oncology and rare‑disease research amplify the Single Cell RNA Sequencing market size and attract venture capital.

4. What challenges could impede market growth?

Challenges comprise data‑analysis complexity, limited standardization across platforms, and stringent regulatory requirements for clinical diagnostics. Moreover, high upfront instrument costs and scarcity of skilled bioinformaticians may slow adoption in smaller research labs and emerging markets.

5. Which regions are leading the Single Cell RNA Sequencing market?

North America remains the dominant region, accounting for over 40 % of revenue, driven by extensive R&D funding and biotech clusters. Europe follows closely, while Asia‑Pacific exhibits the fastest growth rate, propelled by expanding pharmaceutical pipelines and government genomics initiatives.

6. Who are the top companies competing in this space?

Leading vendors include 10x Genomics, Illumina, BGI Group, Thermo Fisher Scientific, and NanoString Technologies. These firms differentiate through integrated library‑prep kits, scalable automation, and robust analytics pipelines, securing sizable market share in both research and clinical segments.

7. What future opportunities are emerging for the market?

Future opportunities arise from integrating spatial transcriptomics, multi‑omics profiling, and AI‑driven data interpretation. Partnerships with pharmaceutical companies for drug target discovery and the rollout of CLIA‑certified assays will broaden the market’s future outlook beyond academic research.

8. How is technology shaping the Single Cell RNA Sequencing market?

Advances in droplet microfluidics, barcoding chemistries, and high‑throughput sequencing platforms reduce per‑cell costs and increase throughput to millions of cells per run. These technological leaps accelerate discovery timelines and expand applications in complex tissue atlasing.

9. What is the current regulatory landscape for single‑cell assays?

The regulatory environment varies by jurisdiction; FDA guidance on molecular diagnostics increasingly references single‑cell assays for oncology biomarkers. In Europe, the IVDR framework mandates rigorous validation, while Asian regulators are formulating standards, influencing the market’s future outlook.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Single Cell RNA Sequencing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.32 billion
Revenue forecast in 2033	4.05 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	PerkinElmer; Illumina; Dolomite Bio; TAKARA BIO; Thermo Fisher; Roche; Oxford Nanopore Technologies; Qiagen; LC Sciences; Pacific Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options